Zebrafish as a Research Model for Studying Cannabinoid Effects ↗
Review highlights zebrafish as a valuable model for cannabinoid research, offering advantages in high-throughput screening and developmental studies.
Browse more cannabis research, findings, methods, and limitations.
Review highlights zebrafish as a valuable model for cannabinoid research, offering advantages in high-throughput screening and developmental studies.
Cannabis use may help patients on lower methadone doses remain in treatment, suggesting a potential moderating role in opioid use disorder care.
Cannabis use was associated with less illicit opioid use among methadone patients on lower doses, suggesting potential as a harm reduction adjunct.
Computational model confirms CBD and valproate combination increases liver enzyme elevation risk, explaining clinical observations of hepatotoxicity.
Mining over 1 million web posts reveals extensive cancer patient interest in complementary medicine including cannabis, highlighting information gaps.
Adolescent cannabinoid exposure in rats produced sex-dependent, long-lasting changes in brain metabolism during morphine withdrawal in adulthood.
Adolescent risk factors including peer use and early initiation predict adult substance problems across two independent longitudinal samples.
Review compares cyclic vomiting syndrome and cannabis hyperemesis syndrome, two conditions sharing severe episodic vomiting but differing in cause and treatment.
International physician survey finds standard addiction criteria poorly fit patients prescribed cannabis for chronic pain, raising diagnostic concerns.
Rare randomized trial compares acute cannabis effects in teens vs adults and tests whether CBD modulates these effects differently by age.
Multi-site Global South study confirms cannabis-psychosis associations are not limited to Western populations, expanding the global evidence base.
Analytical study maps distinct terpene profiles in cannabis leaves vs flowers, advancing understanding of the entourage effect.
Four weeks of CBD treatment showed cognitive improvements in cannabis use disorder patients, adding potential dual benefit to CUD treatment.
Animal study shows combined prenatal alcohol and THC exposure impairs spatial and working memory, with potentially distinct effects from either alone.
Multilevel analysis reveals distinct risk and protective factors that differentiate frequent from non-frequent marijuana use in high school students.
OPTIMISE study data examines whether cannabis triggers relapse in first-episode schizophrenia or whether symptom recurrence drives cannabis use.
Study compares three brief screening tools for adolescent substance use disorders, evaluating which performs best for clinical identification.
Human liver cell model establishes CBD concentration thresholds for hepatotoxicity, providing quantitative safety data for dosing guidelines.
Review explores how the endocannabinoid system may influence Alzheimers disease, highlighting cannabinoid therapeutic potential for neuroinflammation and neurodegeneration.
Chilean study finds parenting practices like monitoring and communication are associated with teen alcohol and cannabis use, informing Latin American prevention.
Case report documents fainting (syncope) associated with chronic cannabis use, proposing excessive vagal nerve activation as the mechanism.
Survey reveals variable knowledge and stigmatizing attitudes toward opioid maintenance treatment among Israeli specialist physicians.
Pilot survey reveals cannabis users treatment preferences for use disorder, highlighting gaps between patient wants and available interventions.
Review argues for clear medical messaging that pregnant individuals should pause all cannabinoid use, citing growing fetal risk evidence.
Review examines the growing problem of substance use disorders in older adults, highlighting unique diagnostic and treatment challenges in this population.
Review examines cannabinoids (endogenous, plant, and synthetic) as potential TBI treatments, noting neuroprotective properties and the absence of approved alternatives.
Female athletes who regularly use cannabis showed reduced early anaerobic power, suggesting performance impact in explosive activities.
Study reveals major state-level disparities in prescribing FDA-approved cannabinoids to Medicaid patients, highlighting inequitable access.
Marijuana vaporizer aerosol impairs blood vessel function similarly to smoke, challenging the perception that vaporizing is significantly safer for cardiovascular health.
Rapid review finds emerging evidence for CBD as a harm reduction tool for problematic substance use, with potential across multiple drug categories.
Blood neurotrophin levels may predict transition to mental disorders in individuals at ultra-high risk for psychosis, offering potential biomarker applications.
ADHD symptoms and sex moderate the effectiveness of cannabis protective strategies, suggesting harm reduction may need tailoring for neurodivergent students.
Delta-8 THC boomed after the 2018 Farm Bill accidentally legalized it, but this scoping review found almost no human safety data behind the millions of products being sold.
Review explores how different cannabinoids modulate sleep through the endocannabinoid system, with potential as new sleep disorder treatments.
CBG reduced key inflammatory markers in rheumatoid arthritis cells through the TRPA1 pain-sensing channel, with selectivity for inflamed over healthy tissue.
Lab study shows CBD has anti-inflammatory effects on B cells and immune cells in rheumatoid arthritis tissue co-cultures, clarifying therapeutic mechanisms.
Comprehensive review examines CBDs therapeutic potential across neurological, psychiatric, inflammatory, and cardiovascular conditions beyond pain relief.
Hemp seed oil showed antidepressant effects in perimenopausal depression model through HPA axis regulation and estrogen-like activity.
Brain error processing is impaired in cannabis use disorder and correlates with reduced self-awareness of addiction, helping explain low treatment-seeking.
Clinical framework helps healthcare providers evaluate cannabis product quality and safety, addressing a practical gap in medical cannabis care.
CBD effects on neuropathic pain differ by anxiety phenotype in rats, supporting personalized approaches to cannabinoid pain treatment.
Comprehensive overview of analytical methods for detecting and quantifying cannabinoids in cannabis products, supporting regulatory and safety needs.
Meta-analysis finds associations between cannabis use and bipolar disorder onset and clinical features, extending the cannabis-mental health evidence base.
Current smoking is linked to worse cognition in stabilized schizophrenia, challenging the self-medication hypothesis that nicotine helps thinking.
Fast centrifugal partition chromatography effectively isolates pure CBD and CBDA from hemp extract while removing all THC contamination.
Review examines the evidence base for cannabis driving safety policies, highlighting challenges in connecting THC levels to actual impairment.
Cannabis use disorder rates increased among US veterans with chronic pain from 2005-2019, highlighting risks of expanded cannabis access in pain populations.
Randomized trial tests how a standardized medical cannabis dose affects simulated driving and eye movement, informing fitness-to-drive guidelines.
Hemp roots upregulate heavy metal transporter genes when exposed to cadmium, providing molecular insight into phytoremediation potential and contamination risk.
Users describe synthetic cannabinoid addiction as profoundly more severe than natural cannabis, with intense compulsion and physical dependence themes.